Lucideon to Co-host Drug-free Antibacterial Technology Forum
Lucideon is hosting a forum in conjunction with HyMedPoly, a European Union Horizon 2020 funded project, and the Cambridge Network. The forum will be held on December 14th at the Entrepreneurship Centre in Cambridge.
Infection has become one of the toughest problems in the medical world. As bacteria become more resistant to drugs, materials and surfaces are seen as complementary measures for infection control and management. The Drug-free Antibacterial Technology for Medical Applications forum will review advances and needs in these technologies from business, clinical and research perspectives.
Lucideon's Dr Mark Cresswell, senior scientist, healthcare, will be presenting on "The development of antibacterial inorganic materials and their potential for new medical technologies".
He said: "This forum is bringing together professionals and academics to discuss the developments in a medical technology field that is increasingly important. The risk from resistance to antibiotic drugs is a major concern in the medical world, driven by overuse and misuse of antibiotics.
"Drug-free technologies offer a solution to this issue as they don’t promote resistance and can significantly reduce the chances of bacterial growth. Many technologies focus on prevention rather than cure, reducing the number of infections and so the reliance and use of antibiotics and therefore bringing down the risk of resistance to antibiotics. The forum provides an opportunity for speakers to present and discuss on the latest findings and technology advances. My own focus will be on inorganic materials with antibacterial properties for use in technologies."
Lucideon partners with clients across the globe to support their materials challenges throughout the lifecycle of their products. Through expert consultancy, technology development, and testing and characterization services, Lucideon works as an extension to its clients' teams, providing quicker routes to market, competitive advantage, regulatory approvals, and game-changing materials science. With technical expertise, industry experience, and analytical and materials know-how, Lucideon works across a range of segments, including orthopaedics, vascular, dental, consumer healthcare, pharmaceutical, wound care, and medical devices.
HyMedPoly has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant programme No. 643050.
06 November, 2018